The observation that pretreatment DCP levels did not show significant differences between groups suggests that while DCP is a strong indicator of treatment response, it must be considered alongside other clinical factors including tumor size, which emerged as another significant predictor in our analysis. This evidence concerns the gene ACE and neoplasm.